This database contains 231 studies, archived under the term: "ADLs/IADLs"
Click here to filter this large number of results.
Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer’s disease: secondary analyses from a randomized, controlled trial
Kamphuis, P. J. G. H.,
Verhey, F. R. J.,
Olde Rikkert, M. G. M.,
Twisk, J. W. R.,
Swinkels, S. H. N.,
Scheltens, P.
Objectives: To investigate the effect of a medical food (Souvenaid) on body mass index (BMI) and functional abilities in patients with mild Alzheimer’s disease (AD). DESIGN/SETTING/PARTICIPANTS/INTERVENTION /MEASUREMENTS: These analyses were performed on data from a 12-week, double-blind, randomized, controlled, multicenter, proof-of-concept study with a similarly designed and exploratory 12-week extension period. Patients with mild AD […]
Evaluation of a Medical and Mental Health Unit compared with standard care for older people whose emergency admission to an acute general hospital is complicated by concurrent ‘confusion’: a controlled clinical trial. Acronym: TEAM: Trial of an Elderly Acute care Medical and mental health unit
Harwood, Rowan H.,
Goldberg, Sarah E.,
Whittamore, Kathy H.,
Russell, Catherine,
Gladman, John Rf,
Jones, Rob G.,
Porock, Davina,
Lewis, Sarah A.,
Bradshaw, Lucy E.,
Elliot, Rachel A.
Background: Patients with delirium and dementia admitted to general hospitals have poor outcomes, and their carers report poor experiences. We developed an acute geriatric medical ward into a specialist Medical and Mental Health Unit over an eighteen month period. Additional specialist mental health staff were employed, other staff were trained in the ‘person-centred’ dementia care […]
Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer’s disease
Background: Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer’s disease (AD).; Methods: Post hoc analysis of a 24-week, prospective, international, randomized, double-blind, placebo- and active-controlled trial. Patients (n = 892) with probable AD received rivastigmine transdermal patches (9.5 mg/24 hours [10 cm(2)]), […]
Non-pharmacological, multicomponent group therapy in patients with degenerative dementia: a 12-month randomizied, controlled trial
Graessel, Elmar,
Stemmer, Renate,
Eichenseer, Birgit,
Pickel, Sabine,
Donath, Carolin,
Kornhuber, Johannes,
Luttenberger, Katharina
Background: Currently available pharmacological and non-pharmacological treatments have shown only modest effects in slowing the progression of dementia. Our objective was to assess the impact of a long-term non-pharmacological group intervention on cognitive function in dementia patients and on their ability to carry out activities of daily living compared to a control group receiving the […]
Memantine in everyday clinical practice: a comparison of studies in Germany and Greece
Förstl, H.,
Stamouli, S. S.,
Janetzky, W.,
Galanopoulos, A.,
Karageorgiou, C.,
Tzanakaki, M.
Background/aims: Results from German and Greek non-interventional studies were compared to investigate possible differences concerning efficacy, tolerability and compliance between both countries.; Methods: In two open-label, multicentre, non-interventional studies, 4,305 patients with mild to severe Alzheimer’s disease (AD) were treated with daily doses of 20 mg memantine for 6 months. Efficacy was assessed using the […]
MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia
Ashford, J. W.,
Adamson, M.,
Beale, T.,
La, D.,
Hernandez, B.,
Noda, A.,
Rosen, A.,
O'Hara, R.,
Fairchild, J. K.,
Spielman, D.,
Yesavage, J. A.
Objectives: Magnetic Resonance Spectroscopy (MRS) may provide a precise and reliable assessment of the extent and severity of neural tissue loss caused by various diseases. In particular, the N-Acetyl Aspartate (NAA) and Creatine (Cr) ratio has been found to be an indicator of the degree of neuronal loss in Alzheimer’s disease (AD). Memantine is thought […]
A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer’s disease
Articus, K.,
Baier, M.,
Tracik, F.,
Kühn, F.,
Preuss, U. W.,
Kurz, A.
Background: Cholinesterase inhibitors form the mainstay of treatment for persons with mild-to-moderate Alzheimer’s disease (AD). The rivastigmine patch may increase compliance and the proportion of patients maintaining an efficacious dose compared with oral cholinesterase inhibitors.; Objective: To investigate the proportion of patients who reached and maintained the target rivastigmine patch dose compared with the target […]